NTLA - Intellia Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $21.64 DETAILS

Stock News

Intellia Therapeutics Appoints Jing L. Marantz, M.D.

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company's translational, development, regulatory and medical affairs functions.

Oct 13, 2026 03:30 AM • globenewswire.com

Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and United Therapeutics (NASDAQ: UTHR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Profitability This table compares Intellia Therapeutics and United

Oct 11, 2026 09:58 PM • defenseworld.net

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Oct 09, 2026 04:56 AM • zacks.com

Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at Barclays

Barclays assumed coverage on shares of Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set an "underweight" rating and a $8.00 price target on the stock. Barclays's price target would indicate a potential downside of 31.68% from the stock's current price. Other research analysts have

Oct 08, 2026 03:41 AM • defenseworld.net

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on October 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

Oct 02, 2026 12:01 PM • globenewswire.com

Financial Review: Intellia Therapeutics (NASDAQ:NTLA) vs. Bicycle Therapeutics (NASDAQ:BCYC)

Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 86.2% of Bicycle

Sep 20, 2026 10:16 PM • defenseworld.net

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event.

Sep 18, 2026 08:02 PM • marketbeat.com

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

Sep 18, 2026 06:46 AM • zacks.com

Intellia Therapeutics (NASDAQ:NTLA) Stock Crosses Below Fifty Day Moving Average – What’s Next?

Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) shares passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $12.10 and traded as low as $11.37. Intellia Therapeutics shares last traded at $11.49, with a volume of 4,586,846 shares traded. Analyst Upgrades and Downgrades

Sep 16, 2026 11:24 PM • defenseworld.net

Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 14, 2026 02:41 PM • seekingalpha.com

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

Sep 09, 2026 07:05 AM • zacks.com

3 Promising Genomics Stocks in the Spotlight in 2026

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

Sep 08, 2026 09:50 AM • zacks.com

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world's first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.

Sep 08, 2026 04:00 AM • globenewswire.com

Public Employees Retirement System of Ohio Invests $1.49 Million in Intellia Therapeutics, Inc. $NTLA

Public Employees Retirement System of Ohio acquired a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 88,257 shares of the company's stock, valued at approximately $1,493,000. Public Employees Retirement System of Ohio

Sep 07, 2026 11:53 PM • defenseworld.net

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

Sep 04, 2026 12:05 PM • globenewswire.com

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points

Sep 04, 2026 04:50 AM • globenewswire.com

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.

Sep 04, 2026 04:00 AM • globenewswire.com

Bank of New York Mellon Corp Makes New $6.95 Million Investment in Intellia Therapeutics, Inc. $NTLA

Bank of New York Mellon Corp purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 410,654 shares of the company's stock, valued at approximately $6,948,000. Bank of New York Mellon Corp owned approximately

Sep 03, 2026 11:17 PM • defenseworld.net

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.

Aug 31, 2026 07:22 AM • fool.com

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

Aug 24, 2026 07:01 AM • zacks.com